AU2007281876B2 - FcgammaRIIB-specific antibodies and methods of use thereof - Google Patents

FcgammaRIIB-specific antibodies and methods of use thereof Download PDF

Info

Publication number
AU2007281876B2
AU2007281876B2 AU2007281876A AU2007281876A AU2007281876B2 AU 2007281876 B2 AU2007281876 B2 AU 2007281876B2 AU 2007281876 A AU2007281876 A AU 2007281876A AU 2007281876 A AU2007281876 A AU 2007281876A AU 2007281876 B2 AU2007281876 B2 AU 2007281876B2
Authority
AU
Australia
Prior art keywords
antibody
antibodies
fragment
fcyriib
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2007281876A
Other languages
English (en)
Other versions
AU2007281876A1 (en
Inventor
Robyn Gerena
Ling Huang
Leslie S. Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Macrogenics Inc
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of AU2007281876A1 publication Critical patent/AU2007281876A1/en
Application granted granted Critical
Publication of AU2007281876B2 publication Critical patent/AU2007281876B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2007281876A 2006-06-26 2007-06-26 FcgammaRIIB-specific antibodies and methods of use thereof Active AU2007281876B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81668806P 2006-06-26 2006-06-26
US60/816,688 2006-06-26
PCT/US2007/072153 WO2008019199A2 (en) 2006-06-26 2007-06-26 FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF

Publications (2)

Publication Number Publication Date
AU2007281876A1 AU2007281876A1 (en) 2008-02-14
AU2007281876B2 true AU2007281876B2 (en) 2013-09-05

Family

ID=39033547

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007281876A Active AU2007281876B2 (en) 2006-06-26 2007-06-26 FcgammaRIIB-specific antibodies and methods of use thereof

Country Status (15)

Country Link
US (4) US8785599B2 (OSRAM)
EP (2) EP2505209A1 (OSRAM)
JP (3) JP5764290B2 (OSRAM)
AU (1) AU2007281876B2 (OSRAM)
CA (1) CA2656222C (OSRAM)
CY (1) CY1118098T1 (OSRAM)
DK (1) DK2029173T3 (OSRAM)
ES (1) ES2599319T3 (OSRAM)
HU (1) HUE030269T2 (OSRAM)
IL (1) IL195573A0 (OSRAM)
LT (1) LT2029173T (OSRAM)
PL (1) PL2029173T3 (OSRAM)
PT (1) PT2029173T (OSRAM)
SI (1) SI2029173T1 (OSRAM)
WO (1) WO2008019199A2 (OSRAM)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1380290A1 (en) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
WO2004063351A2 (en) 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
JP2007536932A (ja) 2004-05-10 2007-12-20 マクロジェニクス，インコーポレーテッド ヒト化ＦｃγＲＩＩＢ特異的抗体とその利用法
US7632497B2 (en) * 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP2314618A3 (en) 2004-11-12 2011-10-19 Xencor Inc. Fc variants with altered binding to FcRn
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US8114832B2 (en) * 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
SI2029173T1 (sl) 2006-06-26 2016-12-30 Macrogenics, Inc. Protitelesa, specifična za Fc RIIB, in postopki za njihovo uporabo
EP2032159B1 (en) 2006-06-26 2015-01-07 MacroGenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
WO2009151717A2 (en) 2008-04-02 2009-12-17 Macrogenics, Inc. Bcr-complex-specific antibodies and methods of using same
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
EP2023143A1 (en) * 2007-08-06 2009-02-11 Boehringer Ingelheim Vetmedica Gmbh Immunogenic streptococcus proteins
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
JP5781762B2 (ja) * 2007-08-10 2015-09-24 プロテリックス、インク ユニバーサルｉｉｉ型フィブロネクチン結合ドメインのライブラリ
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US20090309617A1 (en) * 2007-08-24 2009-12-17 Ye Fang Biosensor antibody functional mapping
KR101616758B1 (ko) 2007-12-26 2016-04-29 젠코어 인코포레이티드 ＦｃＲｎ에 대한 변경된 결합성을 갖는 Ｆｃ 변이체
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
BRPI0906309A2 (pt) 2008-04-02 2020-05-26 Macrogenics, Inc Imunoglobulina, anticorpo, uso do anticorpo e composição farmacêutica
WO2009126819A1 (en) 2008-04-09 2009-10-15 Advanced Immune Therapeutics, Inc. Methods for improving the bioactivity of therapeutic ige antibodies for the treatment of disease
CA2726845C (en) 2008-06-04 2017-09-26 Macrogenics, Inc. Antibodies with altered binding to fcrn and methods of using same
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
PT2405928T (pt) 2009-03-11 2017-02-07 Promedior Inc Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade
AU2010262847B2 (en) 2009-06-17 2016-06-02 Promedior, Inc. SAP variants and their use
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CA2776385C (en) 2009-10-07 2019-04-09 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
PH12018501083A1 (en) 2010-03-04 2019-02-18 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
EP2663647A4 (en) 2011-01-14 2015-08-19 Redwood Bioscience Inc POLYPEPTIDE IMMUNOGLOBULINS WITH ALDEHYDIC MARKING AND THEIR USE METHOD
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
CA2926418A1 (en) * 2013-10-08 2015-04-16 Promedior, Inc. Methods for treating fibrotic cancers
US10526391B2 (en) 2014-07-22 2020-01-07 The University Of Notre Dame Du Lac Molecular constructs and uses thereof
TWI870335B (zh) 2015-06-12 2025-01-21 美商宏觀基因股份有限公司 變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
EP3442574A4 (en) 2016-04-15 2019-12-11 MacroGenics, Inc. Novel B7-H3 binding MOLECULES, ANTIBODY-ACTIVE CONJUGATES AND METHOD OF USE THEREOF
US11208632B2 (en) 2016-04-26 2021-12-28 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
US12460000B2 (en) 2018-09-07 2025-11-04 Itabmed (Hk) Limited Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
KR102688094B1 (ko) * 2019-11-29 2024-07-25 주식회사 대웅제약 Cobll1 단백질 특이 항체 또는 이의 항원 결합 단편, 및 이의 용도
IL272389A (en) 2020-01-30 2021-08-31 Yeda Res & Dev Kits containing antibodies to PD-L1 and their uses in therapy
WO2022140697A1 (en) * 2020-12-23 2022-06-30 The Regents Of The University Of California Methods of treating respiratory disorders
WO2024092031A1 (en) 2022-10-25 2024-05-02 Seismic Therapeutic, Inc. VARIANT IgG FC POLYPEPTIDES AND USES THEREOF

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005115452A2 (en) * 2004-04-16 2005-12-08 Macrogenics, Inc. Fcϝriib-specific antibodies and methods of use thereof
AU2006279945A1 (en) * 2005-08-10 2007-02-22 Macrogenics, Inc. Identification and engineering of antibodies with variant FC regions and methods of using same

Family Cites Families (251)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US598520A (en) 1898-02-08 Marker s record for laundrymen
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3378250D1 (en) 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4752601A (en) * 1983-08-12 1988-06-21 Immunetech Pharmaceuticals Method of blocking immune complex binding to immunoglobulin FC receptors
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5985599A (en) * 1986-05-29 1999-11-16 The Austin Research Institute FC receptor for immunoglobulin
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (en) * 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
FR2626882B1 (fr) * 1988-02-08 1991-11-08 Ire Celltarg Sa Conjugues de derives de vinca comportant une chaine detergente en position c-3
US4861579A (en) 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
AU3740089A (en) 1988-05-27 1989-12-12 Schering Biotech Corporation Human fc-gamma receptor iii
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU4308689A (en) 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5576184A (en) * 1988-09-06 1996-11-19 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens
ATE159982T1 (de) * 1988-09-15 1997-11-15 Univ Columbia Antikörper mit modifiziertem kohlenhydratgehalt und verfahren zur herstellung und verwendung
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US20030229208A1 (en) 1988-12-28 2003-12-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8913737D0 (en) 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
AU641673B2 (en) 1989-06-29 1993-09-30 Medarex, Inc. Bispecific reagents for aids therapy
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
GB8916400D0 (en) * 1989-07-18 1989-09-06 Dynal As Modified igg3
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
WO1991005548A1 (en) 1989-10-10 1991-05-02 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
CA2071867A1 (en) 1989-11-06 1991-05-07 Edith Mathiowitz Method for producing protein microspheres
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
FI85768C (fi) 1990-07-04 1992-05-25 Valtion Teknillinen Foerfarande foer utfoerning av ytplasmonresonansmaetning samt i foerfarandet anvaendbar givare.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2092323A1 (en) 1990-10-01 1992-04-02 George Y. Wu Targeting viruses and cells for selective internalization by cells
ATE175118T1 (de) 1990-10-05 1999-01-15 Medarex Inc Gezielte immunostimulierung mit bispezifischen stoffen
US5364930A (en) * 1990-10-16 1994-11-15 Northwestern University Synthetic C1q peptide fragments
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
KR100246529B1 (ko) 1990-12-14 2000-04-01 스티븐 에이. 서윈. 엠.디. 수용체 관련된 신호 변환 경로를 위한 키메라 사슬
GB9105245D0 (en) 1991-03-12 1991-04-24 Lynxvale Ltd Binding molecules
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
JP3431140B2 (ja) 1991-04-26 2003-07-28 サーフィス・アクティブ・リミテッド 抗体およびその使用方法
DE69232706T2 (de) 1991-05-01 2002-11-28 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Rockville Verfahren zur behandlung infektiöser respiratorischer erkrankungen
EP0584279B1 (en) 1991-05-14 2001-03-14 The University Of Connecticut Targeted delivery of genes encoding immunogenic proteins
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
CA2103371C (en) 1991-06-05 2003-09-16 George Y. Wu Targeted delivery of genes encoding secretory proteins
DE69110032T2 (de) 1991-06-08 1995-12-21 Hewlett Packard Gmbh Verfahren und Gerät zur Feststellung und/oder Konzentrationsbestimmung von Biomolekülen.
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US6800738B1 (en) * 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
AU2238292A (en) 1991-06-14 1993-01-12 Xoma Corporation Microbially-produced antibody fragments and their conjugates
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US6787153B1 (en) 1991-06-28 2004-09-07 Mitsubishi Chemical Corporation Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
US5223408A (en) * 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
SE9102808L (sv) 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
AU2605592A (en) * 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
WO1993014188A1 (en) 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Targeted virus
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
WO1993017715A1 (en) 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
CA2133411A1 (en) 1992-04-03 1993-10-14 Alexander T. YOUNG Gene therapy using targeted viral vectors
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
ATE452975T1 (de) 1992-08-21 2010-01-15 Univ Bruxelles Immunoglobuline ohne leichte ketten
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
CA2141602A1 (en) 1992-08-26 1994-03-03 Philip Leder Use of the cytokine ip-10 as an anti-tumor agent
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CH686365A5 (de) 1992-10-06 1996-03-15 Werner Hofliger Mobilkran.
ATE200625T1 (de) 1992-10-09 2001-05-15 Advanced Tissue Sciences Inc Leberreservezellen
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
CA2145641C (en) 1992-12-03 2008-05-27 Richard J. Gregory Pseudo-adenovirus vectors
US5441050A (en) 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
EP0682710B1 (en) * 1993-02-10 2003-10-29 Unilever Plc Isolation process using immobilized proteins with specific binding capacities
WO1994025570A1 (en) 1993-04-23 1994-11-10 Sloan-Kettering Institute For Cancer Research Method for screening for targets for anti-inflammatory or anti-allergic agents
US5877396A (en) 1993-04-23 1999-03-02 Sloan Kettering Institute For Cancer Research Mice mutant for functional Fc receptors and method of treating autoimmune diseases
ATE204325T1 (de) 1993-04-29 2001-09-15 Unilever Nv Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
EP0711303B2 (en) * 1993-07-30 2009-06-10 Affymax, Inc. Biotinylation of proteins
GB9316989D0 (en) 1993-08-16 1993-09-29 Lynxvale Ltd Binding molecules
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
AU691225B2 (en) * 1993-11-10 1998-05-14 Schering Corporation Improved interferon polymer conjugates
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
PT1231268E (pt) 1994-01-31 2005-11-30 Univ Boston Bancos de anticorpos policlonais
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JPH10503371A (ja) 1994-07-29 1998-03-31 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規化合物
US6132764A (en) * 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US6962686B2 (en) 1994-10-12 2005-11-08 California Institute Of Technology Cell-specific gene delivery vehicles
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
AU4755696A (en) 1995-01-05 1996-07-24 Board Of Regents Acting For And On Behalf Of The University Of Michigan, The Surface-modified nanoparticles and method of making and using same
DK0813525T3 (da) 1995-03-10 2004-02-16 Berlex Lab Benzamidinderivater, deres fremstilling og anvendelse som antikoagulanter
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6410690B1 (en) * 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
JP2000507912A (ja) 1995-08-31 2000-06-27 アルカームズ コントロールド セラピューティックス，インコーポレイテッド 作用剤の徐放性組成物
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US5942328A (en) 1996-02-29 1999-08-24 International Business Machines Corporation Low dielectric constant amorphous fluorinated carbon and method of preparation
ES2190799T5 (es) 1996-03-01 2008-08-16 Novartis Ag Inmunogenos peptidicos para vacunacion y tratamiento contra la alergia.
JP2000506165A (ja) 1996-03-04 2000-05-23 ザ ペン ステイト リサーチ ファウンデーション 細胞インターナリゼーションを増強するための物質および方法
AU5711196A (en) 1996-03-14 1997-10-01 Human Genome Sciences, Inc. Apoptosis inducing molecule i
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1997034911A1 (en) 1996-03-22 1997-09-25 Human Genome Sciences, Inc. Apoptosis inducing molecule ii
BR9708387A (pt) 1996-03-28 2000-01-04 Genitrix Llc Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada.
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6699658B1 (en) * 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6300065B1 (en) * 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
CA2262405A1 (en) 1996-08-02 1998-02-12 Bristol-Myers Squibb Company A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
US6025485A (en) * 1997-02-14 2000-02-15 Arcaris, Inc. Methods and compositions for peptide libraries displayed on light-emitting scaffolds
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6339069B1 (en) * 1996-10-15 2002-01-15 Elan Pharmaceuticalstechnologies, Inc. Peptide-lipid conjugates, liposomes and lipsomal drug delivery
GB9623820D0 (en) 1996-11-16 1997-01-08 Secr Defence Surface plasma resonance sensor
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
ES2236832T3 (es) 1997-01-16 2005-07-16 Massachusetts Institute Of Technology Preparacion de particulas para inhalacion.
WO1998034957A1 (en) 1997-02-11 1998-08-13 Immunomedics, Inc. STIMULATION OF AN IMMUNE RESPONSE WITH ANTIBODIES LABELED WITH THE α-GALACTOSYL EPITOPE
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
SI0970126T1 (en) 1997-04-14 2001-08-31 Micromet Ag Novel method for the production of antihuman antigen receptors and uses thereof
US20030207346A1 (en) * 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
DE19721700C1 (de) 1997-05-23 1998-11-19 Deutsches Krebsforsch Mutierter OKT3-Antikörper
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
AU4754397A (en) 1997-10-15 1999-05-03 Medarex, Inc. Bispecific molecules directed to tumor associated glycoprotein-72 and fc receptor
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
CA2248971A1 (en) * 1997-10-31 1999-04-30 Kyowa Hakko Kogyo Co., Ltd. .beta.1, 3-n-acetylglucosaminyltransferase, dna encoding it and its use
ATE384732T1 (de) 1997-11-03 2008-02-15 Human Genome Sciences Inc Vegi, ein inhibitor der angiogenese und des tumorwachstums
US5843597A (en) 1997-12-01 1998-12-01 Eveready Battery Company, Inc. Ribbed gasket for miniature galvanic cell
WO1999041285A1 (en) 1998-02-17 1999-08-19 Medarex, Inc. Treating and diagnosing macrophage-mediated diseases using fc receptor ligands
PL199659B1 (pl) 1998-02-25 2008-10-31 Merck Patent Gmbh Białko fuzyjne przeciwciała hu-KS IL2, cząsteczka DNA kodująca białko fuzyjne przeciwciała hu-KS IL2 i sposób wytwarzania białka fuzyjnego przeciwciała hu-KS IL2
US6455263B2 (en) * 1998-03-24 2002-09-24 Rigel Pharmaceuticals, Inc. Small molecule library screening using FACS
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6242195B1 (en) * 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6455677B1 (en) 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
EP0953639A1 (en) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
CA2319429A1 (en) 1998-05-20 1999-11-25 Graffinity Pharmaceutical Design Gmbh Surface plasmon resonance sensor for the simultaneous measurement of a plurality of samples in fluid form
BR9910642A (pt) 1998-05-22 2001-10-09 Avanir Pharmaceuticals Análogos de benzimidazol como reguladores descendentes de ige
US6289286B1 (en) 1998-05-29 2001-09-11 Biacore Ab Surface regeneration of biosensors and characterization of biomolecules associated therewith
JP2002518432A (ja) 1998-06-24 2002-06-25 アドバンスト インハレーション リサーチ，インコーポレイテッド 吸入器から放出される大多孔性粒子
US6218419B1 (en) * 1998-07-08 2001-04-17 Harbor Branch Oceanographic Institution, Inc. Aminoiminoquinone and aminoquinone alkaloid compounds and methods of use
US6696550B2 (en) * 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
WO2000009560A2 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6311415B1 (en) 1998-09-14 2001-11-06 Lind Shoe Company Bowling shoe with replaceable tip
US6899871B2 (en) 1998-10-01 2005-05-31 University Of Southern California Gene delivery system and methods of use
US7315786B2 (en) * 1998-10-16 2008-01-01 Xencor Protein design automation for protein libraries
DK1124568T3 (da) 1998-10-21 2008-01-02 Altor Bioscience Corp Polyspecifikke bindingsmolekyler og anvendelser deraf
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7780882B2 (en) 1999-02-22 2010-08-24 Georgetown University Simplified and improved method for preparing an antibody or an antibody fragment targeted immunoliposome for systemic administration of a therapeutic or diagnostic agent
SI2857516T1 (sl) * 2000-04-11 2017-09-29 Genentech, Inc. Multivalentna protitelesa in njihove uporabe
WO2001079299A1 (en) * 2000-04-13 2001-10-25 The Rockefeller University Enhancement of antibody-mediated immune responses
AU2001270609A1 (en) 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
EP1497318A4 (en) 2001-04-18 2006-03-01 Dyax Corp BINDING MOLECULES FOR FC ZONE POLYPEPTIDES
ES2437875T3 (es) * 2001-04-30 2014-01-14 Eli Lilly And Company Anticuerpos humanizados que reconocen el péptido beta-amiloide
US6972324B2 (en) * 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
EP2316485A1 (en) * 2001-10-12 2011-05-04 Schering Corporation Use of bispecific antibodies to regulate immune responses
ES2326964T3 (es) 2001-10-25 2009-10-22 Genentech, Inc. Composiciones de glicoproteina.
AU2003206264A1 (en) 2002-02-07 2003-09-02 Vereniging Voor Christelijk Wetenschappelijk Onderwijs MODULATING TOLERANCE BY MODULATING FcGammaRIIB RECEPTOR SIGNALLING
US20040002587A1 (en) * 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
EP1546203B1 (en) * 2002-08-01 2012-06-20 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
CA2495251C (en) * 2002-08-14 2018-03-06 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
US8187593B2 (en) * 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
FR2844513B1 (fr) 2002-09-13 2007-08-03 Lab Francais Du Fractionnement Anticorps pour adcc et induisant la production de cytokines.
FR2844455B1 (fr) 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
KR100980065B1 (ko) 2002-09-27 2010-09-03 젠코어 인코포레이티드 최적화된 Ｆｃ 변이체 및 그의 제조 방법
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
WO2004063351A2 (en) * 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
DE10303664A1 (de) * 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US7059141B2 (en) * 2003-04-29 2006-06-13 Imi Cornelius Inc. Combined ice and beverage dispenser and icemaker
AR044388A1 (es) * 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
AU2003265522A1 (en) 2003-08-18 2005-03-10 Macrogenics, Inc. FCGammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
PT1706424E (pt) 2004-01-12 2009-10-01 Applied Molecular Evolution Variantes da região fc
JP2007536932A (ja) 2004-05-10 2007-12-20 マクロジェニクス，インコーポレーテッド ヒト化ＦｃγＲＩＩＢ特異的抗体とその利用法
KR20190126461A (ko) * 2004-07-22 2019-11-11 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
PL1776384T3 (pl) 2004-08-04 2013-10-31 Mentrik Biotech Llc WARIANTY REGIONÓW Fc
US7662926B2 (en) * 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
US7655229B2 (en) * 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
BRPI0515589A (pt) 2004-09-02 2008-07-29 Genentech Inc polipeptìdeos ou anticorpos de ligação de antìgeno isolado, anticorpo isolado, método para regular de forma negativa a atividade de fc(gama)riib, métodos de tratamento, anticorpos biespecìficos isolados, métodos de inibição de uma resposta imune, de supressão na liberação de histamina, de ativação de fc(gama)riib, de inibição da expressão do receptor fc(épsilon)ri, composição e kit
US7632497B2 (en) * 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
CA2590935C (en) 2004-12-15 2014-09-30 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
WO2006113665A2 (en) 2005-04-15 2006-10-26 Macrogenics, Inc. Covalent diabodies and uses thereof
US20080286819A1 (en) * 2005-11-07 2008-11-20 Ravetch Jeffrey V Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof
SG170110A1 (en) 2006-03-10 2011-04-29 Macrogenics Inc Identification and engineering of antibodies with variant heavy chains and methods of using same
US7786270B2 (en) * 2006-05-26 2010-08-31 Macrogenics, Inc. Humanized FcγRIIB-specific antibodies and methods of use thereof
SI2029173T1 (sl) 2006-06-26 2016-12-30 Macrogenics, Inc. Protitelesa, specifična za Fc RIIB, in postopki za njihovo uporabo
EP2032159B1 (en) 2006-06-26 2015-01-07 MacroGenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
ES2656359T3 (es) 2006-06-30 2018-02-26 Novo Nordisk A/S Anticuerpos anti-NKG2A y usos de los mismos
WO2008140603A2 (en) * 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
WO2009151717A2 (en) 2008-04-02 2009-12-17 Macrogenics, Inc. Bcr-complex-specific antibodies and methods of using same
US8802089B2 (en) 2008-01-03 2014-08-12 Genmab A/S Monoclonal antibodies against CD32B

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005115452A2 (en) * 2004-04-16 2005-12-08 Macrogenics, Inc. Fcϝriib-specific antibodies and methods of use thereof
AU2006279945A1 (en) * 2005-08-10 2007-02-22 Macrogenics, Inc. Identification and engineering of antibodies with variant FC regions and methods of using same

Also Published As

Publication number Publication date
US20080044429A1 (en) 2008-02-21
CA2656222A1 (en) 2008-02-14
WO2008019199A2 (en) 2008-02-14
US10100116B2 (en) 2018-10-16
EP2029173A2 (en) 2009-03-04
US20150023964A1 (en) 2015-01-22
WO2008019199A8 (en) 2015-10-29
EP2029173B1 (en) 2016-07-20
PT2029173T (pt) 2016-11-02
JP2009541492A (ja) 2009-11-26
CA2656222C (en) 2018-07-17
HUE030269T2 (en) 2017-04-28
EP2505209A1 (en) 2012-10-03
WO2008019199A3 (en) 2008-07-31
PL2029173T3 (pl) 2017-04-28
US8785599B2 (en) 2014-07-22
EP2029173A4 (en) 2010-01-06
JP2016074684A (ja) 2016-05-12
IL195573A0 (en) 2011-08-01
DK2029173T3 (en) 2016-11-07
AU2007281876A1 (en) 2008-02-14
US20190218288A1 (en) 2019-07-18
LT2029173T (lt) 2016-11-10
JP5764290B2 (ja) 2015-08-19
CY1118098T1 (el) 2017-06-28
US20220177574A1 (en) 2022-06-09
SI2029173T1 (sl) 2016-12-30
US11098125B2 (en) 2021-08-24
ES2599319T3 (es) 2017-02-01
JP2014014362A (ja) 2014-01-30

Similar Documents

Publication Publication Date Title
US11098125B2 (en) FcγRIIB-specific antibodies and methods of use thereof
AU2005247301B2 (en) FCγRIIB-specific antibodies and methods of use thereof
CA2565874C (en) Humanized fc.gamma.riib-specific antibodies and methods of use thereof
CA2660592C (en) Humanized fc.gamma.riib-specific antibodies and methods of use thereof
CA2495251C (en) Fc.gamma.riib-specific antibodies and methods of use thereof
CA2590935A1 (en) Fc.gamma.riib-specific antibodies and methods of use thereof
WO2005018669A1 (en) Fcϝriib-specific antibodies and methods of use thereof
HK1121949B (en) Fc riib-specific antibodies and methods of use thereof
HK1121691B (en) Humanized fc gamma riib-specific antibodies and methods of use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)